Bandaríkin - enska - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)]. clarithromycin tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)]. clarithromycin tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - mycoplasma pneumoniae, streptococcus pneumoniae, chlamydophila pneumoniae (in adults and pediatric patients) clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who canno

Kanada - enska - Health Canada

ratiopharm inc division of teva canada limited - clarithromycin - tablet - 250mg - clarithromycin 250mg - other macrolides

Kanada - enska - Health Canada

ratiopharm inc division of teva canada limited - clarithromycin - tablet - 500mg - clarithromycin 500mg - other macrolides

Frakkland - franska - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

viatris sante - clarithromycine 500 - comprimé - 500,00 mg - pour un comprimé > clarithromycine 500,00 mg - antibiotiques antibacteriens de la famille des macrolides - classe pharmacothérapeutique : antibactériens à usage systémique - code atc : j01fa09.ce médicament contient de la clarithromycine : un antibiotique de la famille des macrolides.ce médicament est indiqué chez l’adulte dans le traitement de certaines infections bactériennes à germes sensibles.il est également indiqué dans le traitement d’ulcère de l’estomac (duodénal ou gastrique) .

Frakkland - franska - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

viatris sante - clarithromycine 250 - comprimé - 250,00 mg - pour un comprimé > clarithromycine 250,00 mg - antibiotiques antibacteriens de la famille des macrolides - classe pharmacothérapeutique : antibactériens à usage systémique - code atc : j01fa09.ce médicament contient de la clarithromycine : un antibiotique de la famille des macrolides.ce médicament est indiqué chez l’adulte dans le traitement de certaines infections bactériennes à germes sensibles.

Bandaríkin - enska - NLM (National Library of Medicine)

redpharm drug, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - adults (clarithromycin extended-release tablets, usp) clarithromycin extended-release tablets, usp are indicated for the treatment of adults with mild to moderate infection caused by susceptible strains of the designated microorganisms in the conditions listed below: acute maxillary sinusitis due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae. community-acquired pneumonia due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, streptococcus pneumoniae, chlamydophila pneumoniae (twar), or mycoplasma pneumoniae. the efficacy and safety of clarithromycin extended-release tablets, usp in treating other infections for which other formulations of clarithromycin are approved have not been established. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarit

Bandaríkin - enska - NLM (National Library of Medicine)

redpharm drug, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - 1.1 acute bacterial exacerbation of chronic bronchitis clarithromycin tablets, usp are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae[see indications and usage (1.9)] . 1.2 acute maxillary sinusitis clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)] . 1.3 community-acquired pneumonia clarithromycin tablets, usp are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: haemophilus influenzae (in adults) mycoplasma pneumoniae, streptococcus pneumoniae, chlamydophila pneumoniae 1.4 pharyngitis/tonsillitis clarithromycin tablets, usp are indicated for the treatment of mild to moderate

Bandaríkin - enska - NLM (National Library of Medicine)

redpharm drug, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - 1.1 acute bacterial exacerbation of chronic bronchitis clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)]. 1.2 acute maxillary sinusitis clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)]. 1.3 community-acquired pneumonia clarithromycin tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: • haemophilus influenzae (in adults) • mycoplasma pneumoniae, streptococcus pneumoniae, chlamydophila pneumoniae 1.4 pharyngitis/tonsillitis clarithromycin tablets are indicated for the treatment of mild to moderate infections

Bandaríkin - enska - NLM (National Library of Medicine)

blenheim pharmacal, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablet and other antibacterial drugs, clarithromycin tablet should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clarithromycin tablet is indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective

Bandaríkin - enska - NLM (National Library of Medicine)

department of state health services, pharmacy branch - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin extended-release tablets, usp and other antibacterial drugs, clarithromycin extended-release tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clarithromycin extended-release tablets, usp are indicated for the treatment of adults with mild to moderate infection caused by susceptible strains of the designated microorganisms in the conditions listed below: acute maxillary sinusitis due to haemophilus influenzae, moraxella catarrhalis , or streptococcus pneumoniae. acute bacterial exacerbation of chronic bronchitis due to